Gossamer Bio Inc. (NASDAQ: GOSS) reported Q3 EPS of ($0.80), $0.11 worse than the analyst estimate of ($0.69).

“Since the beginning of the third quarter, we have realized substantial progress advancing our diverse pipeline of four clinical-stage programs,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “Notably, this morning we were pleased to announce that we entered into a clinical trial collaboration with Merck to evaluate KEYTRUDA® in combination with GB1275 in selected advanced solid tumors. We believe this combination holds great promise to address a significant unmet need, and we look forward to sharing initial data from our Phase 1/2 study in 2020.”

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.